NUZOLVENCE Drug Patent Profile

✉ Email this page to a colleague

When do Nuzolvence patents expire, and when can generic versions of Nuzolvence launch?

Nuzolvence is a drug marketed by Entasis Therap and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-two patent family members in thirty-seven countries.

The generic ingredient in NUZOLVENCE is zoliflodacin. One supplier is listed for this compound. Additional details are available on the zoliflodacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Nuzolvence

Nuzolvence will be eligible for patent challenges on December 12, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for NUZOLVENCE?
What are the global sales for NUZOLVENCE?
What is Average Wholesale Price for NUZOLVENCE?

Summary for NUZOLVENCE

International Patents:	62
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NUZOLVENCE

NUZOLVENCE is protected by six US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NUZOLVENCE is ⤷ Start Trial.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,839,641	⤷ Start Trial				⤷ Start Trial
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,040,528	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for NUZOLVENCE

When does loss-of-exclusivity occur for NUZOLVENCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 3862
Estimated Expiration: ⤷ Start Trial

Australia

Patent: 09305203
Estimated Expiration: ⤷ Start Trial

Brazil

Patent: 0920180
Estimated Expiration: ⤷ Start Trial

Canada

Patent: 36335
Estimated Expiration: ⤷ Start Trial

Chile

Patent: 11000838
Estimated Expiration: ⤷ Start Trial

China

Patent: 2245605
Estimated Expiration: ⤷ Start Trial

Patent: 4086565
Estimated Expiration: ⤷ Start Trial

Colombia

Patent: 82126
Patent: COMPUESTOS HETEROAROMATICOS FUSIONADOS Y ESPIROCICLICOS PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
Estimated Expiration: ⤷ Start Trial

Costa Rica

Patent: 110195
Patent: COMPUESTOS HETEROAROMÁTICOS ESPIROCÍCLICOS FUSIONADOS PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
Estimated Expiration: ⤷ Start Trial

Cuba

Patent: 110083
Patent: COMPUESTOS HETEROAROMÁTICOS ESPIROCÍCLICOS FUSIONADOS PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
Estimated Expiration: ⤷ Start Trial

Dominican Republic

Patent: 011000102
Patent: COMPUESTOS HETEROAROMATICOS ESPIROCICLICOS FUSIONADOS PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
Estimated Expiration: ⤷ Start Trial

Ecuador

Patent: 11010980
Patent: COMPUESTOS HETEROAROMÁTICOS ESPIROCÍCLICOS FUSIONADOS PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
Estimated Expiration: ⤷ Start Trial

Eurasian Patent Organization

Patent: 1100613
Patent: КОНДЕНСИРОВАННЫЕ, СПИРОЦИКЛИЧЕСКИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ БАКТЕРИАЛЬНЫХ ИНФЕКЦИЙ
Estimated Expiration: ⤷ Start Trial

European Patent Office

Patent: 50077
Patent: COMPOSÉS HÉTÉROAROMATIQUES SPIROCYCLIQUES FUSIONNÉS POUR TRAITER LES INFECTIONS BACTÉRIENNES (FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS)
Estimated Expiration: ⤷ Start Trial

Hong Kong

Patent: 60127
Patent: 用於治療細菌感染的稠合、螺環雜芳族化合物 (FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS)
Estimated Expiration: ⤷ Start Trial

Patent: 03483
Patent: 用於治療細菌感染的稠合、螺環雜芳族化合物 (FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS)
Estimated Expiration: ⤷ Start Trial

Japan

Patent: 49169
Estimated Expiration: ⤷ Start Trial

Patent: 12505261
Patent: 細菌感染の処置用の縮合スピロ環式ヘテロ芳香族化合物
Estimated Expiration: ⤷ Start Trial

Patent: 15178510
Patent: 細菌感染の処置用の縮合スピロ環式ヘテロ芳香族化合物 (FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS)
Estimated Expiration: ⤷ Start Trial

Mexico

Patent: 11003598
Patent: COMPUESTOS HETEROAROMATICOS ESPIROCICLICOS, FUSIONADOS, PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS. (FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS.)
Estimated Expiration: ⤷ Start Trial

South Africa

Patent: 1103533
Patent: FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
Estimated Expiration: ⤷ Start Trial

South Korea

Patent: 1676886
Estimated Expiration: ⤷ Start Trial

Patent: 110090895
Patent: 박테리아 감염의 치료를 위한 융합된 스피로시클릭 헤테로방향족 화합물 (FUSED SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS)
Estimated Expiration: ⤷ Start Trial

Spain

Patent: 65611
Estimated Expiration: ⤷ Start Trial

Taiwan

Patent: 1020258
Patent: Chemical compounds 542
Estimated Expiration: ⤷ Start Trial

Uruguay

Patent: 174
Patent: NUEVOS HETEROCICLOS SUSTITUIDOS, COMPOSICIONES FARMACEUTICAS CONTENIENDOLOS, PROCEDIMIENTOS DE PREPARACION Y APLICACIONES
Estimated Expiration: ⤷ Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUZOLVENCE around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	073862		⤷ Start Trial
Australia	2009305203		⤷ Start Trial
Brazil	PI0920180		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

AI Deep Research

Questions you can ask:

Summary for NUZOLVENCE

When does loss-of-exclusivity occur for NUZOLVENCE?

Make Better Decisions: Try a trial or see plans & pricing